JP2017500057A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500057A5
JP2017500057A5 JP2016553248A JP2016553248A JP2017500057A5 JP 2017500057 A5 JP2017500057 A5 JP 2017500057A5 JP 2016553248 A JP2016553248 A JP 2016553248A JP 2016553248 A JP2016553248 A JP 2016553248A JP 2017500057 A5 JP2017500057 A5 JP 2017500057A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553248A
Other languages
English (en)
Japanese (ja)
Other versions
JP6553069B2 (ja
JP2017500057A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/064621 external-priority patent/WO2015070061A1/en
Publication of JP2017500057A publication Critical patent/JP2017500057A/ja
Publication of JP2017500057A5 publication Critical patent/JP2017500057A5/ja
Application granted granted Critical
Publication of JP6553069B2 publication Critical patent/JP6553069B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553248A 2013-11-07 2014-11-07 抗wt1/hla二重特異性抗体 Expired - Fee Related JP6553069B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361901310P 2013-11-07 2013-11-07
US61/901,310 2013-11-07
US201462037875P 2014-08-15 2014-08-15
US62/037,875 2014-08-15
PCT/US2014/064621 WO2015070061A1 (en) 2013-11-07 2014-11-07 Anti-wt1/hla bi-specific antibody

Publications (3)

Publication Number Publication Date
JP2017500057A JP2017500057A (ja) 2017-01-05
JP2017500057A5 true JP2017500057A5 (Direct) 2018-05-10
JP6553069B2 JP6553069B2 (ja) 2019-07-31

Family

ID=51987482

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553248A Expired - Fee Related JP6553069B2 (ja) 2013-11-07 2014-11-07 抗wt1/hla二重特異性抗体

Country Status (5)

Country Link
EP (1) EP3066130B1 (Direct)
JP (1) JP6553069B2 (Direct)
CN (1) CN106414500B (Direct)
ES (1) ES2742224T3 (Direct)
WO (1) WO2015070061A1 (Direct)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
HK1258444A1 (zh) 2015-10-09 2019-11-15 Immatics Biotechnologies Gmbh 抗wt1/hla特异性抗体
MY194628A (en) 2015-10-23 2022-12-07 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
CA3053010A1 (en) 2017-02-08 2018-08-16 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3054079A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
AU2018258045B2 (en) 2017-04-26 2024-02-29 Eureka Therapeutics, Inc. Chimeric antibody/T-cell receptor constructs and uses thereof
JP7072792B2 (ja) * 2017-12-11 2022-05-23 国立大学法人神戸大学 二重特異性抗体
WO2019122052A2 (en) 2017-12-21 2019-06-27 F. Hoffmann-La Roche Ag Antibodies binding to hla-a2/wt1
JP2021512914A (ja) 2018-02-08 2021-05-20 ドラゴンフライ セラピューティクス, インコーポレイテッド ナチュラルキラー細胞を活性化する多特異的結合タンパク質を伴うがんの併用療法
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
CN112041432A (zh) 2018-02-15 2020-12-04 纪念斯隆-凯特林癌症中心 Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法
SG11202007945UA (en) 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CA3100775A1 (en) * 2018-05-18 2019-11-21 Children's National Medical Center Improved targeted t-cell therapy
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
WO2021202908A1 (en) * 2020-04-02 2021-10-07 The Board Of Regents Of The University Of Texas System Cd5l-binding antibodies and uses for the same
BR112022021884A2 (pt) 2020-05-06 2022-12-20 Dragonfly Therapeutics Inc Proteínas que se ligam a nkg2d, cd16 e clec12a
JP2023542212A (ja) * 2020-09-24 2023-10-05 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト T細胞二重特異性抗体に関連する有害作用の予防又は緩和
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
EP4496812A1 (en) * 2022-03-22 2025-01-29 MorphoSys AG Deimmunized antibodies specific for cd3

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
HRP20110187T1 (hr) * 2003-10-16 2011-04-30 Micromet Ag Multispecifične deimunizirane tvari koje vežu cd3
MX2008008046A (es) * 2005-12-21 2009-03-04 Micromet Ag Moleculas de epha2-bite y usos de las mismas.
PE20141271A1 (es) * 2011-04-01 2014-10-08 Sloan Kettering Inst Cancer Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2

Similar Documents

Publication Publication Date Title
JP2017500057A5 (Direct)
IL265541B2 (en) Bispecific antibodies and compounds containing them for the treatment of cancer
JP2017535257A5 (Direct)
JP2020103301A5 (Direct)
JP2019510733A5 (Direct)
JP2020534250A5 (Direct)
JP2017524715A5 (Direct)
JP2021501162A5 (Direct)
JP2015163068A5 (Direct)
JP2014522850A5 (Direct)
RU2016124540A (ru) Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака
JP2020508334A5 (Direct)
JP2020515247A5 (Direct)
JP2018512379A5 (Direct)
RU2016129517A (ru) Биспецифические антитела к her2 и способы применения
WO2016191246A3 (en) T cell receptor-like antibodies specific for a prame peptide
JP2018508483A5 (Direct)
JP2018513149A5 (Direct)
JPWO2019175223A5 (Direct)
JPWO2019246514A5 (Direct)
JP2016538318A5 (Direct)
RU2013151455A (ru) Антитела и другие молекулы, которые связывают в7-н1 и pd-1
EA201691858A1 (ru) Композиции антител для лечения опухолей
JP2014205674A5 (Direct)
JP2018502840A5 (Direct)